Table 7
Formulation: Liver B-2 | Components, in matching order: 6Ac1-C12 / DOPE / Cholesterol / DMG-PEG2000 | Original molar parts: 15:20:25:2 | Calculated mol%: 24.1935:32.2581:40.3226:3.2258 | Source: Main p.9; SI pp.2–4
sales@dcchemicals.com
6Ac1-C12
Literature records
Search the tables and observations reproduced from the product literature guide. Rows may represent measurements, recipes or experimental context; they are not all independent experiments.
Table 7
Formulation: 3-Comp Lung (DOTAP) | Components, in matching order: 6Ac1-C12 / DOTAP (chloride) / DMG-PEG2000 | Original molar parts: 60:60:1.2 | Calculated mol%: 49.5050:49.5050:0.9901 | Source: Main p.9; SI p.4
Table 7
Formulation: 4-Comp Lung (DOTAP) | Components, in matching order: 6Ac1-C12 / DOTAP (chloride) / Cholesterol / DMG-PEG2000 | Original molar parts: 60:60:40:1.2 | Calculated mol%: 37.2208:37.2208:24.8139:0.7444 | Source: Main p.9; SI pp.4,21
Table 7
Formulation: 5-Comp Lung (DOTAP) | Components, in matching order: 6Ac1-C12 / DOPE / Cholesterol / DMG-PEG2000 / DOTAP (chloride) | Original molar parts: 15:20:25:2:62 | Calculated mol%: 12.0968:16.1290:20.1613:1.6129:50.0000 | Source: Main pp.9–10; SI p.4
Table 7
Formulation: 3-Comp Lung (DDAB) | Components, in matching order: 6Ac1-C12 / DDAB (bromide) / DMG-PEG2000 | Original molar parts: 50:40:0.2 | Calculated mol%: 55.4324:44.3459:0.2217 | Source: Main p.9
Table 7
Formulation: 4-Comp Lung (DDAB) | Components, in matching order: 6Ac1-C12 / DDAB (bromide) / Cholesterol / DMG-PEG2000 | Original molar parts: 50:40:50:0.2 | Calculated mol%: 35.6633:28.5307:35.6633:0.1427 | Source: Main p.9; SI p.20
Table 8
Parameter: Lipid phase | Reported condition: Dissolve the selected lipids in ethanol. | Source: Main p.9, Methods
Table 8
Parameter: RNA phase | Reported condition: 10 mM sodium citrate buffer, pH 4.0. | Source: Main p.9, Methods
Table 8
Parameter: Mixing | Reported condition: Rapidly combine ethanol and aqueous phases at 1:3 v/v; incubate 15 min at room temperature. | Source: Main p.9, Methods
Table 8
Parameter: For in vivo use | Reported condition: Dialyze against 1× PBS for 2 h using Pur-A-Lyzer chambers. | Source: Main p.9, Methods
Table 8
Parameter: Liver loading | Reported condition: 6Ac1-C12:mRNA = 10:1 by mass. | Source: Main p.9, in vitro screening / default formulation
Table 8
Parameter: Three-component lung loading | Reported condition: 6Ac1-C12:mRNA = 20:1 by mass, including the reported DOTAP and DDAB three-component variants. | Source: Main p.9, in vivo delivery
Table 8
Parameter: N/P ratio | Reported condition: Not reported as an N/P value. | Source: Main and SI
Table 9
Formulation: Liver B-2 | Size (nm): 66.70 ± 0.36 | PDI: 0.111 ± 0.017 | Zeta potential (mV): -7.03 ± 2.03 | mRNA binding efficacy (%): 85.67 ± 4.16
Table 9
Formulation: 3-Comp Lung (DOTAP) | Size (nm): 116.83 ± 1.70 | PDI: 0.057 ± 0.021 | Zeta potential (mV): 4.51 ± 1.05 | mRNA binding efficacy (%): 95.10 ± 2.35
Table 9
Formulation: 4-Comp Lung (DOTAP) | Size (nm): 110.47 ± 1.36 | PDI: 0.098 ± 0.031 | Zeta potential (mV): 5.67 ± 1.74 | mRNA binding efficacy (%): 96.79 ± 1.48
Table 9
Formulation: 5-Comp Lung (DOTAP) | Size (nm): 87.48 ± 3.01 | PDI: 0.038 ± 0.020 | Zeta potential (mV): 3.56 ± 0.21 | mRNA binding efficacy (%): 90.71 ± 1.81
Table 9
Formulation: 3-Comp Lung (DDAB) | Size (nm): 257.13 ± 2.21 | PDI: 0.134 ± 0.022 | Zeta potential (mV): Not included in this summary | mRNA binding efficacy (%): 97.41 ± 2.55
Table 10
Formulation: Liver B-2 | Cell subset: Hepatocyte | tdTomato-positive cells (%): 16.87 ± 3.36
Table 10
Formulation: Liver B-2 | Cell subset: Endothelial | tdTomato-positive cells (%): 56.37 ± 13.14
Table 10
Formulation: Liver B-2 | Cell subset: Kupffer | tdTomato-positive cells (%): 34.10 ± 1.32
Table 10
Formulation: 3-Comp Lung (DOTAP) | Cell subset: Endothelial | tdTomato-positive cells (%): 70.77 ± 0.97
Table 10
Formulation: 3-Comp Lung (DOTAP) | Cell subset: Epithelial | tdTomato-positive cells (%): 33.93 ± 0.38
Table 10
Formulation: 3-Comp Lung (DOTAP) | Cell subset: Immune | tdTomato-positive cells (%): 14.37 ± 0.31
Table 11
DOTAP formulation: 3-Comp Lung (DOTAP) | Lung relative fluorescence (%): 70.33 ± 5.13 | Liver relative fluorescence (%): 23.67 ± 1.53
Table 11
DOTAP formulation: 4-Comp Lung (DOTAP) | Lung relative fluorescence (%): 32.67 ± 7.02 | Liver relative fluorescence (%): 48.67 ± 7.02
Table 11
DOTAP formulation: 5-Comp Lung (DOTAP) | Lung relative fluorescence (%): 35.67 ± 13.32 | Liver relative fluorescence (%): 50.67 ± 12.66
Table 12
6Ac1-C12 mass: 10 mg | Amount (μmol): 5.6342 | 1 mM: final volume: 5.6342 mL | 5 mM: final volume: 1.1268 mL | 10 mM: final volume: 0.5634 mL
Table 12
6Ac1-C12 mass: 25 mg | Amount (μmol): 14.0856 | 1 mM: final volume: 14.0856 mL | 5 mM: final volume: 2.8171 mL | 10 mM: final volume: 1.4086 mL
Table 12
6Ac1-C12 mass: 50 mg | Amount (μmol): 28.1712 | 1 mM: final volume: 28.1712 mL | 5 mM: final volume: 5.6342 mL | 10 mM: final volume: 2.8171 mL
Table 12
6Ac1-C12 mass: 100 mg | Amount (μmol): 56.3425 | 1 mM: final volume: 56.3425 mL | 5 mM: final volume: 11.2685 mL | 10 mM: final volume: 5.6342 mL
Table 12
6Ac1-C12 mass: 250 mg | Amount (μmol): 140.8562 | 1 mM: final volume: 140.8562 mL | 5 mM: final volume: 28.1712 mL | 10 mM: final volume: 14.0856 mL